ATE397458T1 - Neue heilmittel für krebs - Google Patents

Neue heilmittel für krebs

Info

Publication number
ATE397458T1
ATE397458T1 AT01954360T AT01954360T ATE397458T1 AT E397458 T1 ATE397458 T1 AT E397458T1 AT 01954360 T AT01954360 T AT 01954360T AT 01954360 T AT01954360 T AT 01954360T AT E397458 T1 ATE397458 T1 AT E397458T1
Authority
AT
Austria
Prior art keywords
cancer
new cure
cure
new
medicament
Prior art date
Application number
AT01954360T
Other languages
English (en)
Inventor
Toshihiro Noguchi
Akemi Baba
Mitsuharu Hanada
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE397458T1 publication Critical patent/ATE397458T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
AT01954360T 2000-07-28 2001-07-26 Neue heilmittel für krebs ATE397458T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2000228239 2000-07-28

Publications (1)

Publication Number Publication Date
ATE397458T1 true ATE397458T1 (de) 2008-06-15

Family

ID=18721568

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01954360T ATE397458T1 (de) 2000-07-28 2001-07-26 Neue heilmittel für krebs

Country Status (13)

Country Link
US (3) US7449181B2 (de)
EP (1) EP1308168B1 (de)
JP (1) JP5117660B2 (de)
KR (1) KR20030019623A (de)
CN (2) CN101732333B (de)
AT (1) ATE397458T1 (de)
AU (1) AU2001276689A1 (de)
CA (1) CA2417255C (de)
DE (1) DE60134324D1 (de)
DK (1) DK1308168T3 (de)
ES (1) ES2307633T3 (de)
TW (1) TWI317285B (de)
WO (1) WO2002009754A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
CN1447696A (zh) * 2000-05-19 2003-10-08 杰南技术公司 用于提高对ErbB拮抗剂癌症治疗的有效应答可能性的基因检测试验
DK1488795T3 (da) * 2002-03-18 2012-05-07 Dainippon Sumitomo Pharma Co Midler til behandling af lungecancer
FR2844455B1 (fr) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement Traitement des pathologies echappant a la reponse immune par des anticorps optimises
WO2006042002A2 (en) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions and methods for treating disease
CN100464783C (zh) * 2004-11-22 2009-03-04 山东蓝金生物工程有限公司 一种含抗肿瘤抗生素的抗癌药物组合物
ES2710439T3 (es) 2005-01-21 2019-04-25 Genentech Inc Dosificación fija de anticuerpos HER
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
US20060204505A1 (en) * 2005-03-08 2006-09-14 Sliwkowski Mark X Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
EP2899541A1 (de) 2007-03-02 2015-07-29 Genentech, Inc. Voraussage der Reaktion auf einen HRE-Dimerisationshemmer auf Basis niedriger HER3-Expression
CA2690334C (en) * 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2009308707A1 (en) 2008-10-31 2010-05-06 Biogen Idec Ma Inc. LIGHT targeting molecules and uses thereof
SG10201402742YA (en) 2009-03-20 2014-08-28 Genentech Inc Bispecific anti-her antibodies
JP5705836B2 (ja) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
KR20130000384A (ko) 2010-02-18 2013-01-02 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 뉴레귤린 길항제 및 암의 치료에서의 그의 용도
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
US20140363438A1 (en) 2011-08-17 2014-12-11 Genentech, Inc. Neuregulin antibodies and uses thereof
US9327023B2 (en) 2011-10-25 2016-05-03 The Regents Of The University Of Michigan HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en) 2011-11-30 2019-07-04 Genentech, Inc. ErbB3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
JP6998646B2 (ja) 2012-11-30 2022-02-04 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ－ｌ１阻害剤併用療法を必要とする患者の同定
WO2017194554A1 (en) 2016-05-10 2017-11-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combinations therapies for the treatment of cancer
CN107349426B (zh) * 2017-07-12 2018-03-23 马骥 阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6075473A (ja) * 1983-09-30 1985-04-27 Sumitomo Chem Co Ltd アミノナフタセン誘導体
US5185432A (en) * 1986-02-26 1993-02-09 Oncogen Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5077220A (en) * 1988-08-26 1991-12-31 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells
JPH035397A (ja) 1989-05-31 1991-01-11 Toshiba Corp 酸化物結晶薄膜の気相成長方法
JP3005397B2 (ja) 1993-09-06 2000-01-31 関西日本電気ソフトウェア株式会社 デッドロック多発自動回避方式
US5686278A (en) * 1994-03-25 1997-11-11 Indiana University Foundation Methods for enhanced retrovirus-mediated gene transfer
CN1164238A (zh) * 1994-09-12 1997-11-05 国际生物免疫有限公司 抗人结肠癌相关抗原的单克隆抗体及其应用
WO1997030035A1 (en) * 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
CN1082187C (zh) * 1996-11-26 2002-04-03 北京市肿瘤防治研究所 一种检测雌激素受体水平的生物试剂及免疫组化方法
ATE244579T1 (de) * 1997-01-22 2003-07-15 Univ Texas Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
US20030068318A1 (en) * 2001-09-28 2003-04-10 O'brien Timothy Treatment of uterine serous papillary cancer

Also Published As

Publication number Publication date
AU2001276689A1 (en) 2002-02-13
EP1308168A1 (de) 2003-05-07
CN1466464A (zh) 2004-01-07
JP5117660B2 (ja) 2013-01-16
CA2417255C (en) 2011-08-02
US9139658B2 (en) 2015-09-22
CA2417255A1 (en) 2003-01-24
TWI317285B (en) 2009-11-21
EP1308168A4 (de) 2004-09-01
US20080031881A1 (en) 2008-02-07
DK1308168T3 (da) 2008-07-28
CN101732333B (zh) 2012-08-15
CN100581585C (zh) 2010-01-20
CN101732333A (zh) 2010-06-16
US20030157097A1 (en) 2003-08-21
ES2307633T3 (es) 2008-12-01
DE60134324D1 (de) 2008-07-17
US7879327B2 (en) 2011-02-01
US7449181B2 (en) 2008-11-11
WO2002009754A1 (en) 2002-02-07
KR20030019623A (ko) 2003-03-06
EP1308168B1 (de) 2008-06-04
US20110104160A1 (en) 2011-05-05

Similar Documents

Publication Publication Date Title
DE60134324D1 (de) NEUE HEILMITTEL FüR KREBS
PT1196172E (pt) (s,s)-reboxetina para tratar a dor cronica
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
MXPA03000905A (es) Compuestos de poliamina ciclicos como tratamiento contra el cancer.
AR027355A1 (es) Acidos tiazolidincarboxilicos
IT1317735B1 (it) Sali di agenti antimicrobici.
DK1525177T3 (da) Substituerede 1,3-diphenylprop-2-en-1-on-derivater, fremstilling og anvendelse deraf
PT1244650E (pt) Derivados arilaminas e sua aplicacao como agentes anti-telomerase
GB0019283D0 (en) Organic compounds
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
MXPA03003632A (es) Metodo para tratamiento de tumores usando terapia de combinacion.
ATE456952T1 (de) Löslich gemachte topoisomerase-gifte
EP1706128A4 (de) Pharmazeutische zusammensetzungen und verfahren für die insulinbehandlung
GB0008305D0 (en) Treatment of fungal infections
ATE430586T1 (de) Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
EE200300082A (et) Farmatseutilne kompositsioon urineerimishäire raviks
ATE368649T1 (de) Cyanoguanidin prodrugs
EE200200605A (et) Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
ES1044983Y (es) Aparato de termoestimulacion para tratamientos terapeuticos.
ES1044082Y (es) Valvula perfeccionada para colchonetas.
NO20053339D0 (no) Levalbuterolsalt.
CY1105142T1 (el) Χρηση υποκατεστημενων ενωσεων 6-διμεθυλαμινομεθυλο-1-φαινυλο-κυκλοεξανιου για τη θepαπεια της ακρατειας ουρων
PT1224181E (pt) Pirrois substituidos uteis como agentes antiproliferativos para o tratamento do cancro

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1308168

Country of ref document: EP